Shiv Prakash Verma

Senior Research Scientist

Memorial Sloan Kettering Cancer Center
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development of improved prevention and treatment approaches. In this study, we conducted pairwise case–case comparisons among five breast cancer subtypes by applying a case–case genome-wide association study (CC-GWAS) approach to summary statistics data of the Breast Cancer Association Consortium. The approach identified 13 statistically significant loci and eight suggestive loci, the majority of which were identified from comparisons between triple-negative breast cancer (TNBC) and luminal A breast cancer. Associations of lead variants in 12 loci remained statistically significant after accounting for previously reported breast cancer susceptibility variants, among which, two were genome-wide significant. Fine mapping implicated putative functional/causal variants and risk genes at several loci, e.g., 3q26.31/ TNFSF10 , 8q22.3/ NACAP1 / GRHL2 , and 8q23.3/ LINC00536 / TRPS1 , for TNBC as compared with luminal cancer. Functional investigation further identified rs16867605 at 8q22.3 as a SNP that modulates the enhancer activity of GRHL2 . Subtype-informative polygenic risk scores (PRS) were derived, and patients with a high subtype-informative PRS had an up to two-fold increased risk of being diagnosed with TNBC instead of luminal cancers. The CC-GWAS PRS remained statistically significant after adjusting for TNBC PRS derived from traditional case–control GWAS in The Cancer Genome Atlas and the African Ancestry Breast Cancer Genetic Consortium. The CC-GWAS PRS was also associated with overall survival and disease-specific survival among patients with breast cancer. Overall, these findings have advanced our understanding of the genetic etiology of breast cancer subtypes, particularly for TNBC. Significance: The discovery of subtype-informative genetic risk variants for breast cancer advances our understanding of the etiologic heterogeneity of breast cancer, which could accelerate the identification of targets and personalized strategies for prevention and treatment.

Year:

2024

Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development of improved prevention and treatment approaches. In this study, we conducted pairwise case–case comparisons among five breast cancer subtypes by applying a case–case genome-wide association study (CC-GWAS) approach to summary statistics data of the Breast Cancer Association Consortium. The approach identified 13 statistically significant loci and eight suggestive loci, the majority of which were identified from comparisons between triple-negative breast cancer (TNBC) and luminal A breast cancer. Associations of lead variants in 12 loci remained statistically significant after accounting for previously reported breast cancer susceptibility variants, among which, two were genome-wide significant. Fine mapping implicated putative functional/causal variants and risk genes at several loci, e.g., 3q26.31/ TNFSF10 , 8q22.3/ NACAP1 / GRHL2 , and 8q23.3/ LINC00536 / TRPS1 , for TNBC as compared with luminal cancer. Functional investigation further identified rs16867605 at 8q22.3 as a SNP that modulates the enhancer activity of GRHL2 . Subtype-informative polygenic risk scores (PRS) were derived, and patients with a high subtype-informative PRS had an up to two-fold increased risk of being diagnosed with TNBC instead of luminal cancers. The CC-GWAS PRS remained statistically significant after adjusting for TNBC PRS derived from traditional case–control GWAS in The Cancer Genome Atlas and the African Ancestry Breast Cancer Genetic Consortium. The CC-GWAS PRS was also associated with overall survival and disease-specific survival among patients with breast cancer. Overall, these findings have advanced our understanding of the genetic etiology of breast cancer subtypes, particularly for TNBC. Significance: The discovery of subtype-informative genetic risk variants for breast cancer advances our understanding of the etiologic heterogeneity of breast cancer, which could accelerate the identification of targets and personalized strategies for prevention and treatment.

Year:

2024

Breast cancer includes several subtypes with distinct characteristic biological, pathologic, and clinical features. Elucidating subtype-specific genetic etiology could provide insights into the heterogeneity of breast cancer to facilitate the development of improved prevention and treatment approaches. In this study, we conducted pairwise case–case comparisons among five breast cancer subtypes by applying a case–case genome-wide association study (CC-GWAS) approach to summary statistics data of the Breast Cancer Association Consortium. The approach identified 13 statistically significant loci and eight suggestive loci, the majority of which were identified from comparisons between triple-negative breast cancer (TNBC) and luminal A breast cancer. Associations of lead variants in 12 loci remained statistically significant after accounting for previously reported breast cancer susceptibility variants, among which, two were genome-wide significant. Fine mapping implicated putative functional/causal variants and risk genes at several loci, e.g., 3q26.31/ TNFSF10 , 8q22.3/ NACAP1 / GRHL2 , and 8q23.3/ LINC00536 / TRPS1 , for TNBC as compared with luminal cancer. Functional investigation further identified rs16867605 at 8q22.3 as a SNP that modulates the enhancer activity of GRHL2 . Subtype-informative polygenic risk scores (PRS) were derived, and patients with a high subtype-informative PRS had an up to two-fold increased risk of being diagnosed with TNBC instead of luminal cancers. The CC-GWAS PRS remained statistically significant after adjusting for TNBC PRS derived from traditional case–control GWAS in The Cancer Genome Atlas and the African Ancestry Breast Cancer Genetic Consortium. The CC-GWAS PRS was also associated with overall survival and disease-specific survival among patients with breast cancer. Overall, these findings have advanced our understanding of the genetic etiology of breast cancer subtypes, particularly for TNBC. Significance: The discovery of subtype-informative genetic risk variants for breast cancer advances our understanding of the etiologic heterogeneity of breast cancer, which could accelerate the identification of targets and personalized strategies for prevention and treatment.

Year:

2024

Collaborators (25)

Montserrat Garcia-Closas

Professor of Epidemiology

Institute of Cancer Research

UNITED KINGDOM
View details

Christopher A. Haiman

University of Southern California

UNITED STATES
View details

Andriy Derkach

Associate Attending Biostatistician

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Christine Ambrosone

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jennifer Hu

Professor

University of Miami

UNITED STATES
View details

Katherine Nathanson

Professor

University of Pennsylvania

UNITED STATES
View details

Xiao‐Ou Shu

Vanderbilt University Medical Center

UNITED STATES
View details

Stefan Ambs

Senior Investigator (tenured) and Head of the Molecular Epidemiology Section

National Cancer Institute

UNITED STATES
View details

Dale Sandler

Branch Chief

National Institute of Environmental Health Sciences

UNITED STATES
View details

Julie R Palmer

Boston University School of Medicine

UNITED STATES
View details

Wei Zheng

-

UNITED STATES
View details

Qiuyin Cai

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Melissa A. Troester

Professor

University of North Carolina at Chapel Hill

UNITED STATES
View details

GUOCHONG JIA

Vanderbilt University

UNITED STATES
View details

Andrew Olshan

University of North Carolina at Chapel Hill

UNITED STATES
View details

Esther John

Professor

Stanford University School of Medicine

UNITED STATES
View details

Charles F. Lynch

-

UNITED STATES
View details

Dezheng Huo

University of Chicago

UNITED STATES
View details

Gordon Watt

Junior Group Leader

The Netherlands Cancer Institute

NETHERLANDS
View details

Xingyi Guo

Associate Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Jirong Long

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Yaohua Yang

Assistant Professor

University of Virginia

UNITED STATES
View details

Jian Gu

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Olufunmilayo I. Olopade

Professor

University of Chicago

UNITED STATES
View details

Christopher Li

Fred Hutchinson Cancer Research Center

UNITED STATES
View details